Journals / Acta Orthopaedica et Traumatologica Turcica / 2021 / Cilt: 55 - Sayı: 3

Serum progranulin to TNF-α ratio in patients with gonarthrosis

Pages
235–238
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results of the study suggest that the activation of the PGRN pathway and/or the inhibition of the TNFαpathway may be essential in terms of the reestablishment of the disrupted inflammatory balance in patients with KOA.Level of Evidence: Level III, Diagnostic study

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Progranulin (PGRN) is a growth factor that has antiinflammatory, immunosuppressive, and chondroprotective effects.It blocks Tumor Necrosis Factor-α (TNF-α) signal pathway by binding its receptor.
📊
Key Findings & Data:The aim of this study was to compare the PGRN levels of patients with Knee OA (KOA) withthat of healthy controls by eliminating the effect of obesity and to evaluate PGRN-to-Tumor Necrosis Factor-α (TNF-α) ratio inKOA, both of which were investigated first in literature by this study.Methods: A total of 80 individuals (40 patients with KOA and 40 healthy controls) were included in this study.
💡
Conclusion & Impact:The results of the study suggest that the activation of the PGRN pathway and/or the inhibition of the TNFαpathway may be essential in terms of the reestablishment of the disrupted inflammatory balance in patients with KOA.Level of Evidence: Level III, Diagnostic study
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Progranulin (PGRN) is a growth factor that has antiinflammatory, immunosuppressive, and chondroprotective effects.It blocks Tumor Necrosis Factor-α (TNF-α) signal pathway by binding its receptor. Recently, it has been claimed that PGRN maybe overexpressed in patients with Osteoarthritis (OA). However, these patients tend to be obese and obesity also may be one ofthe factors that affect PGRN levels. The aim of this study was to compare the PGRN levels of patients with Knee OA (KOA) withthat of healthy controls by eliminating the effect of obesity and to evaluate PGRN-to-Tumor Necrosis Factor-α (TNF-α) ratio inKOA, both of which were investigated first in literature by this study.Methods: A total of 80 individuals (40 patients with KOA and 40 healthy controls) were included in this study. The patients andcontrols were divided into two groups according to their Body Mass Indexes (BMI): nonobese (BMI between 18.5 and 24.9) andobese (BMI of 30 or higher). Each of the groups included 20 subjects and had an equal number of men and women. Blood sampleswere obtained from all participants, and the serum PGRN and TNF-α levels were measured using commercial ELISA kits.Results: There was no difference among groups in terms of age (P = 0.416) and gender distribution. There was no statisticaldifference among study groups with regard to serum PGRN levels. Serum TNF-α levels were significantly higher in obesecontrols (P < 0.001) and nonobese patients (P = 0.003) compared to that of nonobese healthy controls. Correspondingly, serumPGRN-to-TNF-α ratio was considerably lower in obese controls (P < 0.001) and nonobese patients (P < 0.001) by comparison withthat of nonobese healthy controls.Conclusion: We determined that both obesity and KOA increased serum TNF-α levels and concordantly decreased serum PGRNto-TNF-α ratio. The results of the study suggest that the activation of the PGRN pathway and/or the inhibition of the TNFαpathway may be essential in terms of the reestablishment of the disrupted inflammatory balance in patients with KOA.Level of Evidence: Level III, Diagnostic study

🔖

Cite This Article

YILDIZ, K., BOY, F. (2021). Serum progranulin to TNF-α ratio in patients with gonarthrosis. Acta Orthopaedica et Traumatologica Turcica, Cilt: 55 - Sayı: 3, 235–238. https://ajindex.com/articles/353430

References (1)

  1. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745- 1759. 10.1016/S0140-6736(19)30417-9 2. O’Neill TW, McCabe PS, McBeth J. Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. Best Pract Res Clin Rheumatol. 2018;32 (2):312-326. 10.1016/j.berh.2018.10.007 3. Thomas AC, Hubbard-Turner T, Wikstrom EA, Palmieri-Smith RM. Epidemiology of posttraumatic osteoarthritis. J Athl Train. 2017;52(6):491-496. 10.4085/ 1062-6050-51.5.08 4. Carrion M, Frommer KW, Perez-Garcia S, Müller-Ladner U, Gomariz RP, Neumann E. The adipokine network in rheumatic joint diseases. Int J Mol Sci. 2019;20(17):E4091. 10.3390/ijms20174091 5. Abella V, Scotece M, Conde J, et al. The novel adipokine progranulin counteracts IL-1 and TLR4-driven inflammatory response in human and murine chondrocytes via TNFR1. Sci Rep. 2016;6:20356. 10.1038/srep20356 6. Wang T, He C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018;44:38-50. 10.1016/j.cytogfr. 2018.10.002 7. Nadro B, Sztanek F, Lorincz H, Pall D, Paragh G, Harangi M. Diagnostic and prognostic roles of serum progranulin, a novel marker of the carbohydrate metabolism and inflammation. Orv Hetil. 2019;160(25):973-979. 10.1556/650. 2019.31356 8. Mora JC, Przkora R, Cruz-Almeida Y. Knee osteoarthritis: Pathophysiology and current treatment modalities. J Pain Res. 2018;11:2189-2196. 10.2147/JPR. S154002 9. Cerezo LA, Kuklova M, Hulejova H, et al. Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis. Mediators Inflamm. 2015;2015:740357. 10.1155/2015/740357 10. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494-502. 10.1136/ard.16.4.494 11. Schmid A, Hochberg A, Kreiß AF, et al. Role of progranulin in adipose tissue innate immunity. Cytokine. 2020;125:154796. 10.1016/j.cyto.2019.154796 12. Wang F, Chen T, Sun L, et al. Circulating PGRN levels are increased but not associated with insulin sensitivity or β-cell function in Chinese obese children. Dis Markers. 2018;2018:3729402. 10.1155/2018/3729402 13. Alissa EM, Sutaih RH, Kamfar HZ, Alagha AE, Marzouki ZM. Serum progranulin levels in relation to insulin resistance in childhood obesity. J Pediatr Endocrinol Metab. 2017;30(12):1251-1256. 10.1515/jpem-2017-0321 14. Gorkem U, Inal ZO, Inal HA, Bostanci MO. Serum progranulin levels are elevated in infertile women with obesity. Endokrynol Pol. 2018;69(6):661-666. 1